AbbVie cuts 2025 adjusted EPS guidance to $9.90-$9.94 on $1.3 billion Q4 IPR&D expense
AbbVie said its fourth-quarter 2025 results will include $1.3 billion in pre-tax acquired IPR&D and milestones expense, which lowers both GAAP and adjusted diluted EPS by $0.71. The company's full-year 2025 adjusted EPS guidance now falls to $9.90-$9.94 from $10.61-$10.65 excluding the charge, and results for the quarter have not been finalized.
Key points
- Q4 2025 acquired IPR&D and milestones expense: $1.3 billion pre-tax ($1,265 million), reducing EPS by $0.71
- Full-year 2025 adjusted diluted EPS guidance: $9.90-$9.94, including the Q4 expense, versus $10.61-$10.65 previously announced on October 31, 2025 excluding it
- Q4 2025 adjusted diluted EPS guidance: $2.61-$2.65, versus $3.32-$3.36 before the expense; figures are preliminary and subject to closing procedures
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 07, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.